Policies for biosimilar uptake in Europe: an overview
Background Across European countries, differences exist in biosimilar policies, leading to
variations in uptake of biosimilars and divergences in savings all over Europe. Objectives …
variations in uptake of biosimilars and divergences in savings all over Europe. Objectives …
Big data's role in precision public health
S Dolley - Frontiers in public health, 2018 - frontiersin.org
Precision public health is an emerging practice to more granularly predict and understand
public health risks and customize treatments for more specific and homogeneous …
public health risks and customize treatments for more specific and homogeneous …
Irrational use of medicines—a summary of key concepts
R Ofori-Asenso, AA Agyeman - Pharmacy, 2016 - mdpi.com
Medicines play an integral part of healthcare delivery. However, they are expensive
commodities and account for a significant proportion of overall health expenditure in most …
commodities and account for a significant proportion of overall health expenditure in most …
Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa; a preliminary study
JC Meyer, N Schellack, J Stokes, R Lancaster… - Frontiers in …, 2017 - frontiersin.org
Introduction: South Africa has an appreciable burden of both communicable and non-
communicable diseases as well as high maternal, neonatal, and child morbidity. In recent …
communicable diseases as well as high maternal, neonatal, and child morbidity. In recent …
Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study
Background Despite the complexity of drug use, a number of indicators have been
developed, standardized and evaluated by the World Health Organization (WHO). These …
developed, standardized and evaluated by the World Health Organization (WHO). These …
Prospects and challenges of MXenes as emerging sensing materials for flexible and wearable breath‐based biomarker diagnosis
A fully integrated, flexible, and functional sensing device for exhaled breath analysis
drastically transforms conventional medical diagnosis to non‐invasive, low‐cost, real‐time …
drastically transforms conventional medical diagnosis to non‐invasive, low‐cost, real‐time …
Barriers for access to new medicines: searching for the balance between rising costs and limited budgets
B Godman, A Bucsics, P Vella Bonanno… - Frontiers in Public …, 2018 - frontiersin.org
Introduction: There is continued unmet medical need for new medicines across countries
especially for cancer, immunological diseases, and orphan diseases. However, there are …
especially for cancer, immunological diseases, and orphan diseases. However, there are …
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
B Godman, RE Malmström, E Diogene… - Expert review of …, 2015 - Taylor & Francis
Medicines have made an appreciable contribution to improving health. However, even high-
income countries are struggling to fund new premium-priced medicines. This will grow …
income countries are struggling to fund new premium-priced medicines. This will grow …
Use of big data in drug development for precision medicine: an update
Introduction: Big-data-driven drug development resources and methodologies have been
evolving with ever-expanding data from large-scale biological experiments, clinical trials …
evolving with ever-expanding data from large-scale biological experiments, clinical trials …
Integrative review of managed entry agreements: chances and limitations
C Zampirolli Dias, B Godman, LP Gargano… - …, 2020 - Springer
Abstract Background and Objective Managed entry agreements (MEAs) consist of a set of
instruments to reduce the uncertainty and the budget impact of new high-priced medicines; …
instruments to reduce the uncertainty and the budget impact of new high-priced medicines; …